✦ LIBER ✦

Aripiprazole augmentation for treatment of patients with inadequate antidepressants response

✍ Scribed by Chi-Un Pae; Ashwin A. Patkar; Tae-Youn Jun; Chul Lee; Prakash S. Masand; In-Ho Paik

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 123 KB
Volume: 24
Category: Article
ISSN: 1091-4269
DOI: 10.1002/da.20244

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aripiprazole augmentation of incomplete

Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder

✍ Eric A. Storch; Heather Lehmkuhl; Gary R. Geffken; Alexis Touchton; Tanya K. Mur 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Sequential cognitive-behavioral therapy

Sequential cognitive-behavioral therapy for children with obsessive–compulsive disorder with an inadequate medication response: a case series of five patients

✍ Eric A. Storch; Daniel M. Bagner; Gary R. Geffken; Jennifer W. Adkins; Tanya K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

Oral solution of levodopa ethylester for

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

✍ Ruth Djaldetti; Rivkah Inzelberg; Nir Giladi; Amos D. Korczyn; Yehudit Peretz-Ah 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral

Antibody responses to mycobacterial anti

Antibody responses to mycobacterial antigens in patients immunized with BCG for the treatment of neoplastic disease

✍ Dr. Mark H. Kaplan; Donald Armstrong; Carl Pinsky 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

Efficacy of interferon treatment for pat

Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics

✍ Gregory T. Everson; Donald M. Jensen; John R. Craig; Dirk J. van Leeuwen; Vincen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Chronic hepatitis C patients (472 patients) were treated with consensus interferon (CIFN) or interferon (IFN) alfa-2b for 6 months in a large multicenter trial. Efficacy was assessed by clearance of hepatitis C virus (HCV) RNA using reverse transcription polymerase chain reaction (RT-PCR) (F100 copi

Entecavir treatment for chronic hepatiti

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV